A detailed history of Jump Financial, LLC transactions in Acumen Pharmaceuticals, Inc. stock. As of the latest transaction made, Jump Financial, LLC holds 21,200 shares of ABOS stock, worth $41,764. This represents 0.0% of its overall portfolio holdings.

Number of Shares
21,200
Previous 49,367 57.06%
Holding current value
$41,764
Previous $119,000 56.3%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$2.22 - $3.54 $62,530 - $99,711
-28,167 Reduced 57.06%
21,200 $52,000
Q2 2024

Aug 14, 2024

BUY
$2.14 - $4.01 $54,390 - $101,918
25,416 Added 106.12%
49,367 $119,000
Q1 2024

May 13, 2024

SELL
$2.97 - $4.64 $234,775 - $366,787
-79,049 Reduced 76.75%
23,951 $97,000
Q4 2023

Oct 21, 2024

BUY
$1.86 - $4.48 $128,526 - $309,568
69,100 Added 203.83%
103,000 $395,000
Q4 2023

Feb 07, 2024

BUY
$1.86 - $4.48 $128,526 - $309,568
69,100 Added 203.83%
103,000 $395,000
Q3 2023

Oct 21, 2024

BUY
$4.15 - $9.72 $98,425 - $230,529
23,717 Added 232.91%
33,900 $140,000
Q3 2023

Nov 07, 2023

BUY
$4.15 - $9.72 $140,685 - $329,508
33,900 New
33,900 $140,000
Q1 2023

Oct 21, 2024

SELL
$3.75 - $6.65 $146,940 - $260,573
-39,184 Reduced 79.37%
10,183 $41,000
Q1 2023

May 03, 2023

SELL
$3.75 - $6.65 $41,460 - $73,522
-11,056 Reduced 52.06%
10,183 $41,000
Q4 2022

Feb 13, 2023

BUY
$4.81 - $10.17 $102,159 - $216,000
21,239 New
21,239 $114,000
Q1 2022

May 12, 2022

SELL
$3.91 - $6.73 $78,579 - $135,252
-20,097 Closed
0 $0
Q4 2021

Feb 10, 2022

BUY
$6.54 - $15.31 $131,434 - $307,685
20,097 New
20,097 $136,000

Others Institutions Holding ABOS

About Acumen Pharmaceuticals, Inc.


  • Ticker ABOS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,503,100
  • Market Cap $79.8M
  • Description
  • Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Ph...
More about ABOS
Track This Portfolio

Track Jump Financial, LLC Portfolio

Follow Jump Financial, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jump Financial, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jump Financial, LLC with notifications on news.